Publications by authors named "Paul J Masendycz"
Article Synopsis
- RH5 is a promising vaccine candidate against Plasmodium falciparum, showing some effectiveness in reducing parasite growth during human trials, especially when combined with Ripr and CyRPA.
- Researchers tested various combinations of these proteins in mice and rats to determine the best immune response and found that the DPX® adjuvant significantly enhanced the production of protective antibodies.
- While combining RH5 with other antigens showed potential, it may not provide better immunity than using RH5 alone, suggesting that future vaccines could explore different antigen combinations.
A naturally attenuated, human neonatal strain, rotavirus vaccine candidate RV3, was tested in a limited phase II randomized double-blind controlled trial. Doses of 1 ml, containing placebo or 6.5 x 10(5) fluorescent cell forming units (fcfu) of virus in AGMK cells, were given at 3, 5 and 7 months of age.
View Article and Find Full Text PDF